Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asthma drug JYB1904 shows promise in early trial

NCT ID NCT06438757

Disease control Sponsor: Jemincare Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug, JYB1904, in 69 adults with allergic asthma. Participants received either JYB1904 every 8 weeks or the standard drug omalizumab every 2 to 4 weeks for 24 weeks. The goal was to see how the drug behaves in the body, how safe it is, and how well it controls asthma symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JYB1904 (a biologic drug targeting IgE, similar to omalizumab)
What this could lead to
If successful, JYB1904 could offer a new treatment option for allergic asthma, potentially requiring fewer injections than current therapies.
What could go wrong
This is an early Phase IIa trial with only 69 participants, so results may not confirm effectiveness or safety. The drug may not work better than existing treatments or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

69 people

The number who actually took part.

Started

Jun 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide written informed consent voluntarily; * Aged 18-75 years, weight ≥ 40 kg, male or female; * Diagnosed Allergic asthma. Exclusion Criteria: * Prior exposure to anti-IgE therapy within 1 year; * Allergic to anti-IgE biologics; * Current smokers, or quit smoking within 1 year; * Combined with other non-allergic diseases that cause IgE elevation； * History of malignancy, autoimmune diseases, Immune complex mediated diseases, Hypereosinophilic syndrome; * Other conditions unsuitable for the trial judged by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic asthma

Contacts and locations

Locations

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, 201203, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.